699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy

• Omid Hamid,
• Sylvia Lee,
• Hailing Lu,
• Sunandana Chandra,
• Yousef Zakharia,
• Inderjit Mehmi,
• Marya Chaney,
• Graham Watson,
• Patrick Ward,
• Brian P O’Connor,
• Robert M Jotte,
• Amanda Gillespie-Twardy,
• Jason D Berndt,
• Kapil Rathi,
• Scott Knowles,
• Charles Cowey

Affiliations

Omid Hamid

5The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA

Sylvia Lee

Aff137 grid.34477.330000000122986657Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research CenterUniversity of Washington Seattle WA USA

Hailing Lu

11Seattle Genetics, Bothell, WA, USA

Sunandana Chandra

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA

Yousef Zakharia

Department of Medicine, University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA

Inderjit Mehmi

11The Angeles Clinic and Research Institut, Los Angeles, CA, USA

Marya Chaney

7Merck and Co, Inc., Kenilworth, NJ, USA

Graham Watson

East Sussex NHS Health Trust

Patrick Ward

3 Seattle Seahawks, Renton, Washington, USA

Brian P O’Connor

Center for Genes, Environment, & Health, National Jewish Health, Denver, Colorado, USA

Robert M Jotte

8Rocky Mountain Cancer Center, Lone Tree, CO, USA

Amanda Gillespie-Twardy

3US Oncology Network, The Woodlands, TX, USA

Jason D Berndt

12Seagen Inc., Bothell, WA, USA

Kapil Rathi

12Seagen Inc., Bothell, WA, USA

Scott Knowles

12Seagen Inc., Bothell, WA, USA

Charles Cowey

13Texas Oncology – Baylor University, Dallas, TX, USA